Tumor Lysis Syndrome

"Tumor Lysis Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.

Descriptor ID	D015275
MeSH Number(s)	C15.604.515.880 C20.683.515.950
Concept/Terms	Tumor Lysis Syndrome Tumor Lysis Syndrome Syndrome, Tumor Lysis Syndromes, Tumor Lysis Tumor Lysis Syndromes Tumour Lysis Syndrome Syndrome, Tumour Lysis Syndromes, Tumour Lysis Tumour Lysis Syndromes

Below are MeSH descriptors whose meaning is more general than "Tumor Lysis Syndrome".

Diseases [C]
Hemic and Lymphatic Diseases [C15]
Lymphatic Diseases [C15.604]
Lymphoproliferative Disorders [C15.604.515]
Tumor Lysis Syndrome [C15.604.515.880]
Immune System Diseases [C20]
Immunoproliferative Disorders [C20.683]
Lymphoproliferative Disorders [C20.683.515]
Tumor Lysis Syndrome [C20.683.515.950]

Below are MeSH descriptors whose meaning is more specific than "Tumor Lysis Syndrome".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Tumor Lysis Syndrome" by people in this website by year, and whether "Tumor Lysis Syndrome" was a major or minor topic of these publications.

Bar chart showing 21 publications over 10 distinct years, with a maximum of 4 publications in 2005 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	0	1
2004	1	0	1
2005	3	1	4
2010	2	0	2
2011	1	1	2
2013	1	0	1
2015	1	1	2
2018	1	1	2
2019	2	0	2
2020	2	2	4

Below are the most recent publications written about "Tumor Lysis Syndrome" by people in Profiles.

Diao S, Nichols ED, DiNardo C, Konopleva M, Ning J, Qiao W, Maiti A, DiPippo AJ. Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax. Am J Hematol. 2021 03 01; 96(3):E65-E68.

View in: PubMed
Cortes JE, de Lima M, Dombret H, Estey EH, Giralt SA, Montesinos P, Röllig C, Venditti A, Wang ES. Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. J Hematol Oncol. 2020 10 15; 13(1):137.

View in: PubMed
Tambaro FP, Wierda WG. Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. Lancet Haematol. 2020 Feb; 7(2):e168-e176.

View in: PubMed
Martens KL, Khalighi PR, Li S, White AA, Silgard E, Frieze D, Estey E, Garcia DA, Hingorani S, Li A. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. Leuk Res. 2020 02; 89:106298.

View in: PubMed
Khalighi PR, Martens KL, White AA, Li S, Silgard E, Frieze D, Garcia DA, Li A. Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification. J Oncol Pharm Pract. 2020 Apr; 26(3):529-535.

View in: PubMed
Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol. 2019 07; 186(1):184-188.

View in: PubMed
Li J, Meng QH. A Patient with Severe Hyperkalemia. Clin Chem. 2018 11; 64(11):1673.

View in: PubMed
Cao J, Karger AB. Critically Elevated Potassium in a 55-Year-Old Female With Chronic Lymphocytic Leukemia. Lab Med. 2018 Jul 05; 49(3):280-283.

View in: PubMed
Kebriaei P, Cutler C, de Lima M, Giralt S, Lee SJ, Marks D, Merchant A, Stock W, van Besien K, Stelljes M. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018 04; 53(4):449-456.

View in: PubMed
Heikamp E, Dreyer ZE. 50 Years Ago in The Journal of Pediatrics: Prevention and Management of Acute Hyperuricemia in Childhood Leukemia. J Pediatr. 2017 12; 191:178.

View in: PubMed

People

Explore

Similar Concepts

Top Journals